Perceptive Advisors Llc - Apr 30, 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
10%+ Owner
Signature
/s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Stock symbol
ACRV
Transactions as of
Apr 30, 2025
Transactions value $
-$1,017,919
Form type
4
Date filed
5/1/2025, 07:07 PM
Previous filing
Apr 29, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Sale -$617K -438K -11.4% $1.41 3.4M Apr 30, 2025 See Footnote F1, F3
transaction ACRV Common Stock Sale -$401K -299K -8.78% $1.34 3.1M May 1, 2025 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Perceptive Advisors Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.40 to $1.53 inclusive. The reporting persons undertake to provide Acrivon Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.33 to $1.39 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F3 The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.